Dr.RUCHI SHUKLA

Prof.Gupta Ramesh Chandra, Dr. SANJAY KUMAR SINGH, Dr. MOHAN SHALINI

Abstract

Aim:To compare the efficacy of brimonidine, dorzolamide, and brinzolamide in reducing IOP as an adjunctive therapy to a β blocker

Methods: In this prospective case study patients of POAG and OHT were assigned randomly to adjunctive treatment with brimonidine tartrate 0.2% (n = 32), dorzolamide hydrochloride 2% (n = 20), or brinzolamide 1% (n = 24) . Efficacy was evaluated by IOP measurement at baseline, 1 month, 3months,6 months and 1 year

Results:The mean IOP at baseline for Brimonidine , Dorzolamide and Brinzolamide groups had no significant difference . After 6 months of adjunctive treatment, the mean IOP reduction from baseline was 11.51 mmHg ( 40.60 %) with brimonidine, 10.45 mmHg (35.65 %) with dorzolamide, and 10.66 mmHg (35.86 %) with brinzolamide ( P<0.05 for brimonidine vs. dorzolamide and brinzolamide at 6 months follow up ). Conclusions:The addition of brimonidine to beta-blocker provided greater IOP lowering than the addition of either dorzolamide or brinzolamide.